Stephen Kanes is Chief Medical Officer at Sage Therapeutics, Inc. (SAGE). They have made 7 open-market trades across 1 company since 2014, most recently 2026-02-02.
CIK 0001612859
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $54K since 2014, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SAGE | SELL | 2019-02-08 | 2019-02-08 | $150.00 | $3.4M | -3.5% | +2.7% | +12.4% |
| SAGE | SELL | 2018-01-10 | 2018-01-12 | $177.38 | $13.2M | +2.9% | -10.4% | -4.8% |
| SAGE | SELL | 2016-04-19 | 2016-04-21 | $38.00 | $798K | -8.2% | -17.3% | +9.5% |
| SAGE | SELL · 10b5-1 | 2015-09-28 | 2015-09-29 | $46.42 | $279K | -30.6% | -2.1% | -2.1% |
| SAGE | SELL · 10b5-1 | 2015-08-31 | 2015-09-01 | $53.12 | $637K | -30.6% | -2.1% | -2.1% |
| SAGE | SELL · 10b5-1 | 2015-07-27 | 2015-07-29 | $70.24 | $347K | -30.6% | -2.1% | -2.1% |
| SAGE | SELL · 10b5-1 | 2015-06-24 | 2015-06-25 | $74.06 | $444K | -30.6% | -2.1% | -2.1% |
| SAGE | SELL | 2015-03-25 | 2015-03-27 | $51.49 | $278K | -30.6% | -2.1% | -2.1% |
| SAGE | SELL | 2015-02-25 | 2015-02-27 | $42.05 | $252K | -30.6% | -2.1% | -2.1% |
| SAGE | SELL | 2015-01-26 | 2015-01-27 | $37.29 | $224K | -30.6% | -2.1% | -2.1% |
| SAGE | BUY | 2014-07-23 | 2014-07-23 | $18.00 | $54K | -30.6% | -2.1% | -2.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.